The Journal of
Clinical Psychiatry

Schizophrenia/Schizoaffective Disorders

Letter to the Editor May 1, 1999

Weight Gain and Antipsychotic Medications

Ralph Aquila; Marianne Emanuel

J Clin Psychiatry 1999;60(5):336

Article Abstract

Letter to the Editor

Sir: Your recent publication (JCP Visuals, January 1999) unfairly characterizes some atypical antipsychotics as more likely to produce weight gain than risperidone.

Download Free PDF

This PDF is free for all visitors!

Save

Cite

INFORMATION FROM INDUSTRY

AUVELITY is an FDA-approved treatment for adults with MDD. Auvelity, is a rapid-acting antidepressant with a multimodal mechanism, targeting both glutamatergic and monoaminergic pathways. Learn more about how AUVELITY is thought to work and side effects. Please see Important Safety Information within this document and the full Prescribing Information.

Vol 85 • 2024 • Number 4

Read the Current Issue

Meta-Analysis

Changes in Cognition in Patients With Schizophrenia

Systematic Review

Diagnostic Assessment via Telehealth vs Face-to-Face

Original Research

Prevalence, Correlates, and Burden of Subthreshold PTSD in US Veterans

Original Research

Bridge Symptoms Between Borderline Personality and PTSD

Original Research

Gepirone-ER and Sexual Function in Patients with MDD

Original Research

Medication Use and Lines of Treatment in Patients With Insomnia Disorder

View current Issue

Letter to the Editor

Does the Onset of Efficacy for Agitation Vary Depending on the Administration Route of Antipsychotics?

March 20, 2024

As choice of administration route is crucial during psychiatric emergencies, the authors stress the need for RCTs comparing onset of efficacy for agitation across different administration routes of the...

Xintong Mu, Hiroyoshi Takeuchi

Letter to the Editor

Asenapine, Aggression, and Affinity

September 28, 2022

Dr El-Mallakh comments on a recent study by Citrome et al and discusses his group’s research on antiaggression effects of clozapine.

Rif S. El-Mallakh

Letter to the Editor

A Mirror-Image Trial or Smoke and Mirrors? Phase 3b Study on Digital Aripiprazole

August 3, 2022

This letter comments on methodological aspects of a recent study by Cohen et al.

Florian Naudet, André Gillibert, Barbara Mintzes, et al

Weight Gain and Antipsychotic Medications

Read the Current Issue

Changes in Cognition in Patients With Schizophrenia

Diagnostic Assessment via Telehealth vs Face-to-Face

Prevalence, Correlates, and Burden of Subthreshold PTSD in US Veterans

Bridge Symptoms Between Borderline Personality and PTSD

Gepirone-ER and Sexual Function in Patients with MDD

Medication Use and Lines of Treatment in Patients With Insomnia Disorder

ELSEWHERE:

FOLLOW US:

Weight Gain and Antipsychotic Medications

Read the Current Issue

Changes in Cognition in Patients With Schizophrenia

Diagnostic Assessment via Telehealth vs Face-to-Face

Prevalence, Correlates, and Burden of Subthreshold PTSD in US Veterans

Bridge Symptoms Between Borderline Personality and PTSD

Gepirone-ER and Sexual Function in Patients with MDD

Medication Use and Lines of Treatment in Patients With Insomnia Disorder

Related Articles

Does the Onset of Efficacy for Agitation Vary Depending on the Administration Route of Antipsychotics?

Asenapine, Aggression, and Affinity

A Mirror-Image Trial or Smoke and Mirrors? Phase 3b Study on Digital Aripiprazole

Celebrating85 Years

Subscribe to readmore articles

Celebrating
85 Years

Subscribe to read
more articles